Skip to main content

Advertisement

SpringerLink
Log in

Nuclear factor-κB activation in primary lymphoma of bone

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Primary lymphoma of bone is a rare type of extranodal diffuse large B-cell lymphoma with a relatively favourable outcome. Recent scientific interest has focused on elucidating the role of nuclear factor-κB pathway in lymphomagenesis and its potential significance as a therapeutic target. In nodal B-cell non-Hodgkin lymphomas, constitutive activation of nuclear factor-κB appears to be involved in tumour cell survival, notably in the non-germinal centre type of diffuse large B-cell lymphoma. We investigated nuclear factor-κB activation via the classical and alternative pathway in primary lymphoma of bone, through immunohistochemical staining for nuclear factor-κB family members on tumour tissues of 50 patients. Nine cases (18 %) showed nuclear staining for p50, and one case showed nuclear co-expression of p52. None of the cases showed nuclear staining for c-Rel. The nuclear staining of p50 suggests that in a minority of primary lymphomas of bone nuclear factor-κB is constitutively activated via the classical pathway. In contrast to other extranodal types of diffuse large B-cell lymphoma, there was a lack of nuclear co-expression of p65, which might suggest activation of a different pathway. Activation of nuclear factor-κB through the alternative pathway does not appear to be significantly involved, as only one case showed significant nuclear expression for p52. Finally, nuclear expression of p50 was neither preferentially detected in non-germinal centre type or germinal centre type primary lymphoma of bone, nor related to poor prognosis. Therefore, in contrast to nodal diffuse large B-cell lymphoma, the nuclear factor-κB pathway does not appear to be an attractive therapeutic target in primary lymphoma of bone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Unni KK, Hogendoorn PC (2002) Malignant lymphoma. In: Fletcher CDM, Unni KK, Mertens F (eds) World Health Classification of tumours: Pathology amd genetics of tumours of soft tissue and bone. IARC Press, Lyon, pp 306–308

    Google Scholar 

  2. Lopez-Guillermo A, Colomo L, Jimenez M et al (2005) Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 23(12):2797–2804

    Article  PubMed  Google Scholar 

  3. Heyning FH, Kroon HM, Hogendoorn PC, Taminiau AH, van der Woude HJ (2007) MR imaging characteristics in primary lymphoma of bone with emphasis on non-aggressive appearance. Skeletal Radiol 36(10):937–944

    Article  PubMed  Google Scholar 

  4. Beal K, Allen L, Yahalom J (2006) Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 106(12):2652–2656

    Article  PubMed  Google Scholar 

  5. Heyning FH, Hogendoorn PC, Kramer MH et al (1999) Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases. Leukemia 13(12):2094–2098

    Article  PubMed  CAS  Google Scholar 

  6. Heyning FH, Hogendoorn PC, Kramer MH, Holland CT, Dreef E, Jansen PM (2009) Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype. J Clin Pathol 62(9):820–824

    Article  PubMed  CAS  Google Scholar 

  7. Adams H, Tzankov A, d’Hondt S, Jundt G, Dirnhofer S, Went P (2008) Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors. Hum Pathol 39(9):1323–1330

    Article  PubMed  CAS  Google Scholar 

  8. de Leval L, Braaten KM, Ancukiewicz M, Kiggundu E, Delaney T, Mankin HJ, Harris NL (2003) Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation. Am J Surg Pathol 27(9):1269–1277

    Article  PubMed  Google Scholar 

  9. Bhagavathi S, Micale MA, Les K, Wilson JD, Wiggins ML, Fu K (2009) Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature. Am J Surg Pathol 33(10):1463–1469

    Article  PubMed  Google Scholar 

  10. Heyning FH, Jansen PM, Hogendoorn PC, Szuhai K (2010) Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone. J Clin Pathol 63(12):1095–1100

    Google Scholar 

  11. Compagno M, Lim WK, Grunn A et al (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459(7247):717–721

    Article  PubMed  CAS  Google Scholar 

  12. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194(12):1861–1874

    Article  PubMed  CAS  Google Scholar 

  13. Ngo VN, Davis RE, Lamy L et al (2006) A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441(7089):106–110

    Article  PubMed  CAS  Google Scholar 

  14. Lam LT, Davis RE, Pierce J et al (2005) Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11(1):28–40

    PubMed  CAS  Google Scholar 

  15. Harris NL (2008) Mature B-cell neoplasms. In: Swerdlow SH, Campo E, Harris NL et al (eds) World Health Organisation classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 179–267

    Google Scholar 

  16. Choi WW, Weisenburger DD, Greiner TC et al (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15(17):5494–5502

    Article  PubMed  CAS  Google Scholar 

  17. Courts C, Montesinos-Rongen M, Martin-Subero JI et al (2007) Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol 66(3):230–237

    Article  PubMed  CAS  Google Scholar 

  18. Curry CV, Ewton AA, Olsen RJ et al (2009) Prognostic impact of C-REL expression in diffuse large B-cell lymphoma. J Hematop 2(1):20–26

    Article  PubMed  Google Scholar 

  19. Gupta M, Maurer MJ, Wellik LE et al (2012) Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood 120(22):4400–4406

    Article  PubMed  CAS  Google Scholar 

  20. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282

    Article  PubMed  CAS  Google Scholar 

  21. Perkins ND (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8(1):49–62

    Article  PubMed  CAS  Google Scholar 

  22. Sun SC, Ley SC (2008) New insights into NF-kappaB regulation and function. Trends Immunol 29(10):469–478

    Article  PubMed  CAS  Google Scholar 

  23. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8(1):33–40

    Article  PubMed  CAS  Google Scholar 

  24. Espinosa I, Briones J, Bordes R et al (2008) Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications. Histopathology 53(4):441–449

    Article  PubMed  CAS  Google Scholar 

  25. Bhagavathi S, Blenc AM, Amin M et al (2010) Primary cutaneous large B-cell lymphoma shows activation of nuclear factor kappa B and low incidence of Epstein–Barr virus. Am J Dermatopathol 32(5):439–441

    Article  PubMed  Google Scholar 

  26. Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107(3):241–246

    Article  PubMed  CAS  Google Scholar 

  27. Dunleavy K, Pittaluga S, Czuczman MS (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113(24):6069–6076

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank the Netherlands Committee on Bone Tumours for the assistance and availability of clinicopathological material, and I.H. Briaire-de Bruijn for technical assistance in preparing the tissue microarrays.

Conflicts of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands

    Lianne Koens, Pancras C. W. Hogendoorn & Patty M. Jansen

  2. Department of Internal Medicine, Medical Center Haaglanden, The Hague, The Netherlands

    Fenna H. Heyning

  3. First Department of Pathology and Experimental Cancer Research, Faculty of Medicine, Semmelweis University, Budapest, Hungary

    Ágota Szepesi & András Matolcsy

  4. Department of Pathology, Leiden University Medical Center, L1Q, Postbus 9600, 2300 RC, Leiden, The Netherlands

    Patty M. Jansen

Authors
  1. Lianne Koens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fenna H. Heyning
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ágota Szepesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. András Matolcsy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pancras C. W. Hogendoorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Patty M. Jansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patty M. Jansen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koens, L., Heyning, F.H., Szepesi, Á. et al. Nuclear factor-κB activation in primary lymphoma of bone. Virchows Arch 462, 349–354 (2013). https://doi.org/10.1007/s00428-013-1372-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-013-1372-x

Keywords

Search

Navigation